Next-generation rheumatoid factor assay provides improved predictive power for the development of arthritis in patients at risk
Authors' conclusion
The detection of disease-specific RF is feasible and seems to improve the diagnostic power of RF
Study context
- Population
- Patients with seropositive (for IgM-RF or aCCP) arthralgia, followed for 5 years or until arthritis development
- Participants
- 475 patients
- Exposure
- IgM-RF against rheumatoid arthritis (RA)-associated epitope (T3-17 rheumatoid factors (RF)) vs wild-type RF, alone and combined with aCCP
- Outcome
- Progression to arthritis
- Follow-up
- 5 years
Main finding
As reported in the abstract
Risk of arthritis development by RF positivity
Hazard ratio (95% CI)
T3-17 RFvs Wild-type RF
3.2(2.4–4.3)
Wild-type RF
2.2(1.7–3.0)
Observational data: associations, not effects.
Further findings
Arthritis development, T3-17 RF combined with aCCP titres
| HR (CI) | ||
|---|---|---|
| T3-17 RF + aCCPvs HR=5.1 (3.9-6.8); comparator not named in the abstract | 6.4 (4.7–8.7) | |
| 0.10.31310Hazard ratio (log scale) |
- Combination performed better than aCCP detection on its own
Original publication
Next-generation rheumatoid factor assay provides improved predictive power for the development of arthritis in patients at risk. RMD Open. Published 20 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →